source
- Tempus AI to buy cancer test maker Personalis for $1.5 billionTempus AI announced it will acquire Personalis, a California-based company that offers a molecular residual disease test for cancer, in a transaction valued at $1.5 billion. The deal, priced at $1…
- Samsung Biologics to acquire Swiss CDMO PolyPeptide for $1.8 billion, entering peptide API marketSamsung Biologics announced a plan to purchase Swiss contract development and manufacturing organization PolyPeptide for $1.8 billion in cash. The acquisition will extend Samsung Biologics' manufa…